ZA200609111B - Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands - Google Patents

Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands

Info

Publication number: ZA200609111B
Authority: ZA; South Africa
Prior art keywords: histamine; receptor ligands; derivatives useful; tetrahydronaphthyridine derivatives; tetrahydronaphthyridine
Prior art date: 2004-05-12

Application number

ZA200609111A

Other languages

English (en)

Inventor

Lunn Graham

Strang Ross Sinclair

Mathias John Paul

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-12

Filing date

2006-11-01

Publication date

2008-08-27

2006-11-01 Application filed by Pfizer filed Critical Pfizer

2008-08-27 Publication of ZA200609111B publication Critical patent/ZA200609111B/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyridine Compounds (AREA)
Hydrogenated Pyridines (AREA)

ZA200609111A 2004-05-12 2006-11-01 Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands ZA200609111B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04291222A EP1595881A1 (en)	2004-05-12	2004-05-12	Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands

Publications (1)

Publication Number	Publication Date
ZA200609111B true ZA200609111B (en)	2008-08-27

Family

ID=34931096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200609111A ZA200609111B (en)	2004-05-12	2006-11-01	Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands

Country Status (32)

Country	Link
US (2)	US7557121B2 (es)
EP (2)	EP1595881A1 (es)
JP (1)	JP4084410B2 (es)
KR (1)	KR100908155B1 (es)
CN (2)	CN101798305A (es)
AP (1)	AP2006003786A0 (es)
AR (1)	AR049092A1 (es)
AT (1)	ATE491707T1 (es)
AU (1)	AU2005243403B2 (es)
BR (1)	BRPI0510762A (es)
CA (1)	CA2564201C (es)
CR (1)	CR8747A (es)
DE (1)	DE602005025345D1 (es)
DK (1)	DK1756104T3 (es)
EA (1)	EA010487B1 (es)
EC (1)	ECSP066984A (es)
ES (1)	ES2355572T3 (es)
GE (1)	GEP20084552B (es)
GT (1)	GT200500112A (es)
IL (1)	IL178882A (es)
MA (1)	MA28579B1 (es)
MX (1)	MXPA06013113A (es)
NL (1)	NL1029016C2 (es)
NO (1)	NO20064577L (es)
PA (1)	PA8632801A1 (es)
PE (1)	PE20060312A1 (es)
SV (1)	SV2005002112A (es)
TN (1)	TNSN06369A1 (es)
TW (1)	TW200607506A (es)
UY (1)	UY28895A1 (es)
WO (1)	WO2005111036A1 (es)
ZA (1)	ZA200609111B (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6468306B1 (en)	1998-05-29	2002-10-22	Advanced Medical Optics, Inc	IOL for inhibiting cell growth and reducing glare
JP4842835B2 (ja)	2003-12-09	2011-12-21	アボット・メディカル・オプティクス・インコーポレイテッド	折り畳み式眼内レンズおよびその製造方法
JP2008543880A (ja)	2005-06-17	2008-12-04	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ナフチリジン化合物
US8158673B2 (en) *	2005-10-27	2012-04-17	Pfizer Inc.	Histamine-3 receptor antagonists
WO2007052124A1 (en) *	2005-11-04	2007-05-10	Pfizer Limited	Tetrahydronaphthyridine derivative
WO2007099423A1 (en) *	2006-03-02	2007-09-07	Pfizer Products Inc.	1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
US7795262B2 (en)	2006-03-10	2010-09-14	Neurogen Corporation	Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues
MX2008016343A (es)	2006-06-23	2009-01-19	Abbott Lab	Derivados ciclopropil amina como moduladores del receptro de histamina h3.
US9108948B2 (en)	2006-06-23	2015-08-18	Abbvie Inc.	Cyclopropyl amine derivatives
JP5520051B2 (ja) *	2007-11-15	2014-06-11	武田薬品工業株式会社	縮合ピリジン誘導体およびその用途
WO2009082698A1 (en) *	2007-12-21	2009-07-02	Abbott Laboratories	Compositions for treatment of cognitive disorders
US8383657B2 (en)	2007-12-21	2013-02-26	Abbott Laboratories	Thiazolylidine urea and amide derivatives and methods of use thereof
EA201001329A1 (ru) *	2008-02-22	2011-04-29	Айрм Ллк	Соединения и композиции в качестве модуляторов активности gpr119
JP2011518127A (ja) *	2008-03-31	2011-06-23	エヴォテック・アクチエンゲゼルシャフト	ヒスタミンｈ３受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体
WO2010026113A1 (en) *	2008-09-03	2010-03-11	Evotec Neurosciences Gmbh	Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists
WO2010052222A1 (en) *	2008-11-07	2010-05-14	Evotec Neurosciences Gmbh	(dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
EP2421863A1 (en) *	2009-04-21	2012-02-29	NeuroSearch AS	Substituted naphthyridine derivatives and their medical use
US9186353B2 (en)	2009-04-27	2015-11-17	Abbvie Inc.	Treatment of osteoarthritis pain
US8711772B2 (en) *	2009-05-22	2014-04-29	Qualcomm Incorporated	Paging of a user equipment (UE) within a wireless communications system
EP2451281A4 (en) *	2009-07-09	2013-03-13	Merck Sharp & Dohme	TETRAHYDRONAPHTHYDRIN-orexin receptor Antagonist
US8853390B2 (en)	2010-09-16	2014-10-07	Abbvie Inc.	Processes for preparing 1,2-substituted cyclopropyl derivatives
CN102093356B (zh) *	2011-03-16	2012-12-19	无锡美克赛医药科技有限公司	一种2-氯-5,6,7,8-四氢-1,6-萘啶盐酸盐的制备方法
ES2602794T3 (es)	2011-03-31	2017-02-22	Pfizer Inc	Piridinonas bicíclicas novedosas
WO2012172449A1 (en)	2011-06-13	2012-12-20	Pfizer Inc.	Lactams as beta secretase inhibitors
ES2605565T3 (es)	2011-08-31	2017-03-15	Pfizer Inc	Compuestos de hexahidropirano [3,4-D][1,3]tiazin-2-amina
ES2585262T3 (es)	2012-05-04	2016-10-04	Pfizer Inc	Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
KR20150027267A (ko)	2012-06-29	2015-03-11	화이자 인코포레이티드	LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
WO2014045162A1 (en)	2012-09-20	2014-03-27	Pfizer Inc.	ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-ANIME COMPOUNDS
UA110688C2 (uk)	2012-09-21	2016-01-25	Пфайзер Інк.	Біциклічні піридинони
EP2931731A1 (en)	2012-12-11	2015-10-21	Pfizer Inc.	Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
US9403846B2 (en)	2012-12-19	2016-08-02	Pfizer Inc.	Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (en)	2013-02-13	2014-08-21	Pfizer Inc.	HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en)	2013-02-15	2016-01-12	Pfizer Inc.	Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
KR20150119370A (ko)	2013-02-19	2015-10-23	화이자 인코포레이티드	Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
JP6263606B2 (ja)	2013-05-02	2018-01-17	ファイザー・インク	Ｐｄｅ１０阻害剤としてのイミダゾ−トリアジン誘導体
CA2925743C (en)	2013-10-04	2018-03-06	Pfizer Inc.	Novel bicyclic pyridinones as gamma-secretase modulators
US9695171B2 (en)	2013-12-17	2017-07-04	Pfizer Inc.	3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
EP3126361B1 (en)	2014-04-01	2019-11-06	Pfizer Inc	Chromene and 1,1a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
AP2016009493A0 (en)	2014-04-10	2016-10-31	Pfizer	2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
EP3172210B1 (en)	2014-07-24	2020-01-15	Pfizer Inc	Pyrazolopyrimidine compounds
WO2016020786A1 (en)	2014-08-06	2016-02-11	Pfizer Inc.	Imidazopyridazine compounds
MX368391B (es)	2015-02-03	2019-09-30	Pfizer	Ciclopropabenzofuranil-piridopirazindionas novedosas.
DK3303348T3 (da) *	2015-05-28	2019-11-11	Theravance Biopharma R&D Ip Llc	Naphthyridinforbindelser som JAK-kinaseinhibitorer
HUE051898T2 (hu)	2015-06-17	2021-03-29	Pfizer	Triciklusos vegyületek és alkalmazásuk foszfodiészteráz inhibitorokként
JP6873980B2 (ja)	2015-09-14	2021-05-19	ファイザー・インク	ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
EP3353174A1 (en)	2015-09-24	2018-08-01	Pfizer Inc	N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl]amides useful as bace inhibitors
AU2016325665A1 (en)	2015-09-24	2018-03-08	Pfizer Inc.	N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
WO2017051303A1 (en)	2015-09-24	2017-03-30	Pfizer Inc.	Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
PT3419979T (pt)	2016-02-23	2020-03-26	Pfizer	Compostos de 6,7-dihidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida
MX386258B (es)	2016-07-01	2025-03-18	Pfizer	Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas
AU2018230109B2 (en)	2017-03-10	2022-05-12	Pfizer Inc.	Cyclic substituted imidazo[4,5-c]quinoline derivatives
SG11201908322WA (en)	2017-03-10	2019-10-30	Pfizer	Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
CN110997693A (zh)	2017-06-07	2020-04-10	阿德克斯公司	τ聚集抑制剂
KR20200013783A (ko)	2017-06-22	2020-02-07	화이자 인코포레이티드	디히드로-피롤로-피리딘 유도체
EP3668886A2 (en)	2017-08-18	2020-06-24	Adrx, Inc.	Tau aggregation peptide inhibitors
HUE061533T2 (hu)	2018-03-23	2023-07-28	Pfizer	Piperazin azaspiro származékok
EP4297868A4 (en)	2021-02-23	2025-01-08	Hoth Therapeutics, Inc.	USE OF APREPITANT TO TREAT ALZHEIMER'S
WO2022242750A1 (zh) *	2021-05-21	2022-11-24	成都百裕制药股份有限公司	哌嗪衍生物及其在医药上的应用
WO2025145091A1 (en)	2023-12-29	2025-07-03	Pfizer Inc.	Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
NZ331272A (en)	1996-02-09	2000-01-28	Black James Foundation	Histamine H3 receptor ligands
WO2000035298A1 (en)	1996-11-27	2000-06-22	Wm. Wrigley Jr. Company	Chewing gum containing medicament active agents
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
GB9803536D0 (en)	1998-02-19	1998-04-15	Black James Foundation	Histamine H,receptor ligands
EP0982300A3 (en)	1998-07-29	2000-03-08	Societe Civile Bioprojet	Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
TWI298068B (en) *	2000-06-21	2008-06-21	Dainippon Sumitomo Pharma Co	Pharmaceutical composition for schizophrenia
MXPA02012851A (es)	2000-07-13	2003-09-05	Abbott Lab	Pirrolidinas 1,3-disustituidas y 1,3,3-trisustituidas como ligandos del receptor de histamina-3 y sus aplicaciones terapeuticas.
KR100852362B1 (ko)	2000-08-08	2008-08-14	오르토-맥네일 파마슈티칼, 인코퍼레이티드	비-이미다졸 아릴옥시피페리딘
US7186732B2 (en) *	2000-08-08	2007-03-06	Ortho-Mcneil Pharmaceutical, Inc.	Non-imidazole aryloxyalkylamines
WO2002076925A2 (en)	2001-03-23	2002-10-03	Eli Lilly And Company	Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0206033D0 (en) *	2002-03-14	2002-04-24	Pfizer Ltd	Compounds useful in therapy
ATE461178T1 (de)	2003-07-29	2010-04-15	High Point Pharmaceuticals Llc	Pyridazinyl-piperazine und deren verwendung als histamin-h3-rezeptorliganden
WO2007052124A1 (en) *	2005-11-04	2007-05-10	Pfizer Limited	Tetrahydronaphthyridine derivative

2004
- 2004-05-12 EP EP04291222A patent/EP1595881A1/en not_active Withdrawn
2005
- 2005-05-06 CN CN201010150783A patent/CN101798305A/zh active Pending
- 2005-05-06 WO PCT/IB2005/001267 patent/WO2005111036A1/en not_active Ceased
- 2005-05-06 MX MXPA06013113A patent/MXPA06013113A/es active IP Right Grant
- 2005-05-06 KR KR1020067023573A patent/KR100908155B1/ko not_active Expired - Fee Related
- 2005-05-06 EP EP05736116A patent/EP1756104B1/en not_active Expired - Lifetime
- 2005-05-06 DE DE602005025345T patent/DE602005025345D1/de not_active Expired - Lifetime
- 2005-05-06 AP AP2006003786A patent/AP2006003786A0/xx unknown
- 2005-05-06 EA EA200601897A patent/EA010487B1/ru not_active IP Right Cessation
- 2005-05-06 AU AU2005243403A patent/AU2005243403B2/en not_active Ceased
- 2005-05-06 AT AT05736116T patent/ATE491707T1/de not_active IP Right Cessation
- 2005-05-06 BR BRPI0510762-8A patent/BRPI0510762A/pt not_active IP Right Cessation
- 2005-05-06 CN CN2005800150008A patent/CN1950371B/zh not_active Expired - Fee Related
- 2005-05-06 DK DK05736116.4T patent/DK1756104T3/da active
- 2005-05-06 JP JP2007512575A patent/JP4084410B2/ja not_active Expired - Fee Related
- 2005-05-06 GE GEAP20059701A patent/GEP20084552B/en unknown
- 2005-05-06 CA CA2564201A patent/CA2564201C/en not_active Expired - Fee Related
- 2005-05-06 ES ES05736116T patent/ES2355572T3/es not_active Expired - Lifetime
- 2005-05-11 TW TW094115276A patent/TW200607506A/zh unknown
- 2005-05-11 AR ARP050101916A patent/AR049092A1/es unknown
- 2005-05-11 NL NL1029016A patent/NL1029016C2/nl not_active IP Right Cessation
- 2005-05-12 UY UY28895A patent/UY28895A1/es not_active Application Discontinuation
- 2005-05-12 SV SV2005002112A patent/SV2005002112A/es not_active Application Discontinuation
- 2005-05-12 GT GT200500112A patent/GT200500112A/es unknown
- 2005-05-12 US US11/128,804 patent/US7557121B2/en not_active Expired - Fee Related
- 2005-05-12 PE PE2005000533A patent/PE20060312A1/es not_active Application Discontinuation
- 2005-05-12 PA PA20058632801A patent/PA8632801A1/es unknown
2006
- 2006-10-09 NO NO20064577A patent/NO20064577L/no not_active Application Discontinuation
- 2006-10-26 IL IL178882A patent/IL178882A/en not_active IP Right Cessation
- 2006-11-01 ZA ZA200609111A patent/ZA200609111B/xx unknown
- 2006-11-09 EC EC2006006984A patent/ECSP066984A/es unknown
- 2006-11-10 CR CR8747A patent/CR8747A/es unknown
- 2006-11-10 TN TNP2006000369A patent/TNSN06369A1/fr unknown
- 2006-11-10 MA MA29447A patent/MA28579B1/fr unknown
2009
- 2009-06-25 US US12/491,370 patent/US20090258861A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ATE491707T1 (de)	2011-01-15
AR049092A1 (es)	2006-06-28
CN101798305A (zh)	2010-08-11
UY28895A1 (es)	2005-12-30
NL1029016C2 (nl)	2006-05-30
EP1756104A1 (en)	2007-02-28
TW200607506A (en)	2006-03-01
NL1029016A1 (nl)	2005-11-15
SV2005002112A (es)	2005-12-13
US20090258861A1 (en)	2009-10-15
ES2355572T3 (es)	2011-03-29
CN1950371B (zh)	2011-01-12
BRPI0510762A (pt)	2007-11-20
ECSP066984A (es)	2006-12-29
IL178882A (en)	2011-03-31
WO2005111036A1 (en)	2005-11-24
PA8632801A1 (es)	2006-06-02
PE20060312A1 (es)	2006-05-03
EP1595881A1 (en)	2005-11-16
AP2006003786A0 (en)	2006-10-31
EP1756104B1 (en)	2010-12-15
CN1950371A (zh)	2007-04-18
GEP20084552B (en)	2008-11-25
TNSN06369A1 (fr)	2008-02-22
KR100908155B1 (ko)	2009-07-16
AU2005243403B2 (en)	2010-10-07
JP4084410B2 (ja)	2008-04-30
DK1756104T3 (da)	2011-02-21
CA2564201A1 (en)	2005-11-24
JP2007536374A (ja)	2007-12-13
US7557121B2 (en)	2009-07-07
EA200601897A1 (ru)	2007-02-27
EA010487B1 (ru)	2008-10-30
NO20064577L (no)	2006-11-06
KR20070014174A (ko)	2007-01-31
DE602005025345D1 (de)	2011-01-27
MA28579B1 (fr)	2007-05-02
US20050256135A1 (en)	2005-11-17
IL178882A0 (en)	2007-03-08
MXPA06013113A (es)	2007-02-28
AU2005243403A1 (en)	2005-11-24
GT200500112A (es)	2005-12-12
CA2564201C (en)	2011-01-18
CR8747A (es)	2006-12-05

Publication	Publication Date	Title
AP2006003786A0 (en)	2006-10-31	Tetrahydronaphthyridine derivatives useful as histamine H3 receptor ligands
ZA200700683B (en)	2008-08-27	Piperidine derivatives as histamine H3 receptor ligands
ZA200703912B (en)	2008-09-25	3-arylamino pyridine derivatives
TWI369356B (en)	2012-08-01	Tetrahydropyridoindole derivatives
AP2007003887A0 (en)	2007-02-28	Pyridine derivatives
IL180481A0 (en)	2007-06-03	Aryl-pyridine derivatives
ZA200610102B (en)	2008-08-27	Pyrrazolo-pyrimidine derivatives
SI1802307T1 (sl)	2008-08-31	Derivati pirolidina kot ligandi histaminskih receptorjev
IL183140A0 (en)	2007-09-20	Substituted benzoquinolizine derivatives
HUE027689T2 (hu)	2021-12-28	Közbensõ termékek annellált piperazin-2-on-származékok elõállítására
ZA200703172B (en)	2008-08-27	Imidazo-benzodiazepine derivatives
GB0512335D0 (en)	2005-07-27	Merocyanine derivatives
AP2006003840A0 (en)	2006-12-31	Indole-2-carboxamidine derivatives as NMDA receptor antagonists
GB0414272D0 (en)	2004-07-28	OsK1 derivatives
EP1713917A4 (en)	2009-06-17	PNEUMOLYSINE DERIVATIVES
IL179444A0 (en)	2007-05-15	4-phenyl-pyrimidine-2-carbonitrile derivatives
TWI346109B (en)	2011-08-01	4-amino-5-cyanopyrimidine derivatives
SI1636223T1 (sl)	2008-06-30	Derivati benzotiazola kot ligandi receptorja adenozina
IL188924A0 (en)	2008-08-07	Imidazopyridine derivatives as cannabinoid receptor ligands
ZA200705106B (en)	2008-12-31	Nicotinic acetycholine receptor ligands
SG155924A1 (en)	2009-10-29	2-acylaminothiazole derivatives
ZA200800354B (en)	2008-12-31	Imidazopyridine derivatives as cannabinoid receptor ligands
HK1102817A (en)	2007-12-07	Piperidine derivatives as histamine h3 receptor ligands
GB0411078D0 (en)	2004-06-23	Bicyclic derivatives
GB0416524D0 (en)	2004-08-25	Pyridine derivatives